Ph.D candidate
yonsei university, Republic of Korea
I'm a preclinical researcher for the precision medicine of rare cancers. Based on the fusion of clinicopathological data and comprehensive genetic profiling, I validate the drug candidates by the novel patient-derived primary cell model. The most notable property of the novel patient-derived primary cell model is the high concordance of genetic alteration with primary tissue.
Also, I investigate the pathway for the mechanism of action of the drug in the novel patient-derived primary cell model. it leads to the possibility to predict a personal patient's response.